ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Cyclically Adjusted PS Ratio : (As of Jun. 21, 2024)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Cyclically Adjusted PS Ratio?

ImmuneOnco Biopharmaceuticals (Shanghai) does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation

ImmuneOnco Biopharmaceuticals (Shanghai) Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Cyclically Adjusted PS Ratio Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Cyclically Adjusted PS Ratio

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Cyclically Adjusted PS Ratio	-	-	-	-	-

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Cyclically Adjusted PS Ratio falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

ImmuneOnco Biopharmaceuticals (Shanghai) Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Cyclically Adjusted PS Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines